Induction of alpha/beta interferon and dependent nitric oxide synthesis during Chlamydia trachomatis infection of Mc-Coy cells in the absence of exogenous cytokines. Infection and Immunity, 64,3951-3956.
Local excision and mucosal advancement for anorectal ulceration in patients infected with human immunodeficiency virus
✍ Scribed by Dr. E. C. J. Consten; J. F. M. Slors; S. A. Danner; G. J. A. Offerhaus; J. F. W. M. Bartelsman; J. J. B. Van Lanschot
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 470 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0007-1323
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In patients infected with human immunodeficiency virus (HIV) no effective surgical procedure has been described for anorectal ulceration that is resistant to medical thearpy. This study was designed to determine the effectiveness of surgical excision of anorectal ulcers, with or without mucosal advancement. The medical records of patients with HIV and anorectal pathology diagnosed between 1984 and 1994 were reviewed. Patients with anorectal ulcers were divided into group A which was treated only with excision and group B in which excision was combined with mucosal advancement. Surgical treatment was considered successful if relief of symptoms was achieved within 4 weeks of the operation. Excision of anorectal ulcers was successful in seven of 16 patients (44 per cent) in group A. Relief of symptoms was achieved in 12 of 13 patients (92 per cent) in group B when surgical excision was combined with mucosal advancement, which is significantly better than the results in group A (P = 0.02). This non-randomized study indicates that after unsuccessful medical treatment persistent symptomatic ulcers should be treated operatively by excision with mucosal advancement.
📜 SIMILAR VOLUMES
## Variability in CD4 1 T-lymphocyte measurements has been described for both normal and human immunodeficiency virus (HIV)-infected persons. Clinical protocols use CD4 1 cell counts as surrogate markers for disease progression or response. In this study, we determined the variability of CD4 1 T-l
## Abstract ## BACKGROUND Optimal treatment of human immunodeficiency virus (HIV)‐associated non‐Hodgkin lymphoma (NHL) has yet to be defined, because chemotherapy could exacerbate immunodeficiency, with subsequent adverse effects for patients. ## METHODS The authors investigated the feasibility
End-stage liver disease (ESLD) has become the main cause of mortality in patients coinfected by human immunodeficiency virus (HIV) and hepatitis B virus or hepatitis C virus in developed countries. The aim of this study was to describe the natural history of and prognostic factors for ESLD, with par